TATTON研究:奥希替尼联合司美替尼、 savolitinib或度伐利尤单抗治疗EGFR突变肺癌的Ib期多臂试验
TATTON是一项Ib期多臂研究,评估奥希替尼联合司美替尼、savolitinib或度伐利尤单抗在既往EGFR-TKI进展的晚期EGFR突变NSCLC患者中的安全性和耐受性。共77例患者入组,奥希替尼联合司美替尼或savolitinib可在确定的可耐受活性剂量下联合,而联合度伐利尤单抗因间质性肺病报告增加不可行。
要点
- 奥希替尼80mg联合司美替尼或savolitinib在确定的可耐受剂量下可行且具有抗肿瘤活性。
- 奥希替尼联合度伐利尤单抗因间质性肺病报告增加而不可行。
- 常见不良事件包括腹泻、皮疹、恶心和呕吐,多数为1-2级。
核心结论
- 奥希替尼80mg联合司美替尼或savolitinib在确定的可耐受活性剂量下联合可行。
- 奥希替尼联合度伐利尤单抗因间质性肺病报告增加不可行。
研究设计与样本
- 多臂Ib期TATTON研究(NCT02143466),纳入既往EGFR-TKI进展的晚期EGFR突变NSCLC患者。
- 患者分配至奥希替尼80mg每日一次联合司美替尼(25-75mg每日两次,连续或间歇)、savolitinib(600-800mg每日一次)或度伐利尤单抗(3-10mg/kg每2周静脉给药)的剂量递增队列。
- 截至2018年2月28日,共77例患者入组并接受治疗:司美替尼组36例,savolitinib组18例,度伐利尤单抗组23例。
主要发现
- 常见任何级别不良事件(≥20%):司美替尼组腹泻75%、皮疹58%、恶心47%;savolitinib组恶心67%、皮疹56%、呕吐50%;度伐利尤单抗组皮疹48%、呕吐43%、腹泻39%。
- 剂量限制性毒性发生于司美替尼25mg(1例)、50mg(1例)和75mg连续给药组(4例),savolitinib 600mg(1例)和800mg组(2例),以及度伐利尤单抗10mg/kg组(1例)。
- 客观缓解率:司美替尼组42%(95%CI 26%-59%),savolitinib组44%(95%CI 22%-69%),度伐利尤单抗组43%(95%CI 23%-66%)。
关键数值与推荐
- 奥希替尼80mg每日一次联合司美替尼25-75mg每日两次(连续或间歇)或savolitinib 600-800mg每日一次为确定的可耐受活性剂量。
- 奥希替尼联合度伐利尤单抗因间质性肺病报告增加不可行。
临床怎么用
- 对于既往EGFR-TKI进展的EGFR突变NSCLC患者,奥希替尼联合司美替尼或savolitinib可作为进一步研究的联合策略。
- 不推荐奥希替尼联合度伐利尤单抗用于此类患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Osimertinib is a potent, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). The multi-arm phase Ib TATTON study (NCT02143466) was designed to assess the safety and tolerability of osimertinib in combination with other targeted therapies: selumetinib (MEK1/2 inhibitor), savolitinib (MET-TKI), or durvalumab [anti-programmed cell death ligand 1 (anti-PD-L1) monoclonal antibody]. PATIENTS AND METHODS: Patients with advanced EGFR-mutant non-small-cell lung cancer and disease progression on a prior EGFR-TKI were enrolled and allocated to dose-escalating cohorts combining osimertinib 80 mg orally (p.o.) once a day with selumetinib (25-75 mg p.o. twice a day; continuous or intermittent), savolitinib (600-800 mg p.o. once a day), or durvalumab (3-10 mg/kg intravenous every 2 weeks). RESULTS: At data cut-off (28 February 2018), 77 patients were enrolled and received osimertinib plus selumetinib (n = 36), savolitinib (n = 18), or durvalumab (n = 23). Most common adverse events (any grade), occurring in ≥20% of patients across dose groups, were: selumetinib arm-diarrhea (75%), rash (58%), nausea (47%); savolitinib arm-nausea (67%), rash (56%), vomiting (50%); durvalumab arm-rash (48%), vomiting (43%), diarrhea (39%). Dose-limiting toxicities were reported in the selumetinib 25 mg (n = 1), 50 mg (n = 1), and 75 mg (n = 4) continuous-dose groups, savolitinib 600 mg (n = 1) and 800 mg dose groups (n = 2), and durvalumab 10 mg/kg (n = 1) dose group. The objective response rate was 42% (95% confidence interval 26% to 59%), 44% (22% to 69%), and 43% (23% to 66%) in the selumetinib, savolitinib, and durvalumab arms, respectively. CONCLUSION: Our results demonstrate the feasibility of combining osimertinib 80 mg with selumetinib or savolitinib at identified tolerable, active doses. A combination of osimertinib with durvalumab was not feasible due to increased reporting of interstitial lung disease. Osimertinib-based combination therapies represent a compelling approach now being further investigated. CLINICAL TRIALS NUMBER: NCT02143466.
引用
- Oxnard GR, Yang JC, Yu H, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol. 2020. PMID: 32139298. doi:10.1016/j.annonc.2020.01.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。